Funding for this research was provided by:
(P50CA196530, R01CA195720, F31CA203488)
Text and Data Mining valid from 2019-07-10
Received: 6 February 2019
Accepted: 19 June 2019
First Online: 10 July 2019
Ethics approval and consent to participate
: Animal studies were performed in accordance with and with the approval of the Yale University Institutional Animal Care and Use Committee (IACUC).
: Not applicable.
: The authors have the following competing interests to disclose:-Research funding from AstraZeneca (KP, SMK), Roche (KP, SMK, P.-C. H.), Kolltan (KP) and Symphogen (KP), Tempest Therapeutics (SMK).-Consulting/Advisory Role honoraria from AstraZeneca (KP), Merck (KP), Novartis (KP), Tocagen (KP), Pfizer (P.-C. H.), Chugai (P.-C. H.), Elixiron Immunotherapeutics (P.-C. H.), Dynamo Therapeutics (KP), Maverick Therapeutics (KP).-Royalties in IP licensed from MSKCC to Molecular MD (KP).